Innate Pharma (IPHYF) Intangibles (2017 - 2023)

Innate Pharma's Intangibles history spans 7 years, with the latest figure at $447591.0 for Q4 2023.

  • For Q4 2023, Intangibles fell 71.81% year-over-year to $447591.0; the TTM value through Dec 2023 reached $447591.0, down 71.81%, while the annual FY2023 figure was $447591.0, 71.81% down from the prior year.
  • Intangibles reached $447591.0 in Q4 2023 per IPHYF's latest filing, down from $1.6 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $107.3 million in Q4 2019 to a low of $447591.0 in Q4 2023.
  • Average Intangibles over 5 years is $43.0 million, with a median of $50.6 million recorded in 2021.
  • Peak YoY movement for Intangibles: grew 11.25% in 2019, then plummeted 96.86% in 2022.
  • A 5-year view of Intangibles shows it stood at $107.3 million in 2019, then tumbled by 48.58% to $55.2 million in 2020, then decreased by 8.4% to $50.6 million in 2021, then tumbled by 96.86% to $1.6 million in 2022, then plummeted by 71.81% to $447591.0 in 2023.
  • Per Business Quant, the three most recent readings for IPHYF's Intangibles are $447591.0 (Q4 2023), $1.6 million (Q4 2022), and $50.6 million (Q4 2021).